CA2191088A1 - Copolymer-1 improvements in compositions of copolymers - Google Patents

Copolymer-1 improvements in compositions of copolymers

Info

Publication number
CA2191088A1
CA2191088A1 CA002191088A CA2191088A CA2191088A1 CA 2191088 A1 CA2191088 A1 CA 2191088A1 CA 002191088 A CA002191088 A CA 002191088A CA 2191088 A CA2191088 A CA 2191088A CA 2191088 A1 CA2191088 A1 CA 2191088A1
Authority
CA
Canada
Prior art keywords
copolymer
copolymers
compositions
kilodaltons
species
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002191088A
Other languages
French (fr)
Other versions
CA2191088C (en
Inventor
Eliezer Konfino
Michael Sela
Dvora Teitelbaum
Ruth Arnon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yeda Research and Development Co Ltd
Original Assignee
Eliezer Konfino
Michael Sela
Dvora Teitelbaum
Ruth Arnon
Yeda Research And Development Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26939072&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2191088(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Eliezer Konfino, Michael Sela, Dvora Teitelbaum, Ruth Arnon, Yeda Research And Development Co., Ltd. filed Critical Eliezer Konfino
Publication of CA2191088A1 publication Critical patent/CA2191088A1/en
Application granted granted Critical
Publication of CA2191088C publication Critical patent/CA2191088C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G69/00—Macromolecular compounds obtained by reactions forming a carboxylic amide link in the main chain of the macromolecule
    • C08G69/02—Polyamides derived from amino-carboxylic acids or from polyamines and polycarboxylic acids
    • C08G69/08—Polyamides derived from amino-carboxylic acids or from polyamines and polycarboxylic acids derived from amino-carboxylic acids
    • C08G69/10—Alpha-amino-carboxylic acids

Abstract

The present invention relates to an improved composition of copolymer-1 comprising copolymer-1 substantially free of species having a molecular weight of over 40 kilodaltons.
CA002191088A 1994-05-24 1995-05-23 Copolymer-1 improvements in compositions of copolymers Expired - Lifetime CA2191088C (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US24803794A 1994-05-24 1994-05-24
US34424894A 1994-11-23 1994-11-23
US08/248,037 1994-11-23
US08/344,248 1994-11-23
PCT/US1995/006551 WO1995031990A1 (en) 1994-05-24 1995-05-23 Copolymer-1 improvements in compositions of copolymers

Publications (2)

Publication Number Publication Date
CA2191088A1 true CA2191088A1 (en) 1995-11-30
CA2191088C CA2191088C (en) 2004-09-28

Family

ID=26939072

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002191088A Expired - Lifetime CA2191088C (en) 1994-05-24 1995-05-23 Copolymer-1 improvements in compositions of copolymers

Country Status (31)

Country Link
US (11) US5800808A (en)
EP (1) EP0762888B1 (en)
JP (2) JPH10500955A (en)
KR (1) KR100403750B1 (en)
CN (2) CN1174753C (en)
AT (1) ATE212857T1 (en)
AU (1) AU2602195A (en)
BR (2) BRPI9507758B1 (en)
CA (1) CA2191088C (en)
CZ (1) CZ292247B6 (en)
DE (2) DE69525340T2 (en)
DK (1) DK0762888T3 (en)
EE (1) EE03423B1 (en)
ES (1) ES2172586T3 (en)
FI (1) FI120236B (en)
GE (1) GEP20002205B (en)
HK (1) HK1008657A1 (en)
HU (1) HU223473B1 (en)
IL (2) IL113812A (en)
LU (1) LU90987I2 (en)
MD (1) MD1443G2 (en)
NL (1) NL300096I2 (en)
NO (1) NO324528B1 (en)
NZ (1) NZ287335A (en)
PL (1) PL181026B1 (en)
PT (1) PT762888E (en)
SI (1) SI0762888T1 (en)
SK (1) SK283699B6 (en)
TJ (1) TJ392B (en)
UA (1) UA62908C2 (en)
WO (1) WO1995031990A1 (en)

Families Citing this family (129)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5858980A (en) * 1990-03-30 1999-01-12 Autoimmune, Inc. Peptide fragments of myelin basic protein
US7090982B2 (en) 1991-10-22 2006-08-15 The Governors Of The University Of Alberta Methods of predicting therapeutic efficacy of treatment of a multiple sclerosis patient
US6252040B1 (en) 1991-10-22 2001-06-26 The Governors Of The University Of Alberta Peptide specificity of anti-myelin basic protein and the administration of myelin basic protein peptides to multiple sclerosis patients
IL113812A (en) * 1994-05-24 2000-06-29 Yeda Res & Dev Copolymer-1 pharmaceutical compositions containing it and its use
US5858964A (en) * 1995-04-14 1999-01-12 Yeda Research And Development Co. Ltd. Pharmaceutical compositions comprising synthetic peptide copolymer for prevention of GVHD
IL119989A0 (en) * 1997-01-10 1997-04-15 Yeda Res & Dev Pharmaceutical compositions for oral treatment of multiple sclerosis
AU2868699A (en) * 1998-02-13 1999-08-30 Autoimmune, Inc. Treatment of multiple sclerosis using cop-1 and th2-enhancing cytokines
EP1098902A4 (en) 1998-07-23 2002-07-24 Yeda Res & Dev Treatment of autoimmune conditions with copolymer 1 and related copolymers and peptides
AU766498B2 (en) 1998-07-23 2003-10-16 President And Fellows Of Harvard College, The Synthetic peptides and methods of use for autoimmune disease therapies
ES2527760T3 (en) * 1998-07-23 2015-01-29 Yeda Research And Development Co., Ltd. Treatment of Crohn's disease with copolymer 1 and polypeptides
HU229720B1 (en) 1998-09-25 2014-05-28 Yeda Res & Dev Copolymer 1 related polypeptides for us as molecular weight markers and for therapeutic use
US6514938B1 (en) 1998-09-25 2003-02-04 Yeda Research And Development Co. Ltd. At The Weizmann Institute Of Science Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use
US6800287B2 (en) 1998-09-25 2004-10-05 Yeda Research And Development Co., Ltd. Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use
WO2000020010A1 (en) * 1998-10-02 2000-04-13 Yeda Research And Development Co., Ltd. Alternate day administration of copolymer 1 for treating autoimmune diseases
US7083777B1 (en) 1999-04-02 2006-08-01 The Brigham And Women's Hospital, Inc. Immunomodulating polymers
JP4328050B2 (en) * 2000-01-20 2009-09-09 イエダ リサーチ アンド デベロップメント カンパニー リミテッド Use of Copolymer 1, related peptides and polypeptides and T cells treated with them for neuroprotective therapy
ATE329608T1 (en) * 2000-02-18 2006-07-15 Yeda Res & Dev FORMULATIONS OF COPOLYMER 1 (GLATIRAMER ACETATE) FOR ORAL, NASAL AND PULMONARY ADMINISTRATION
US7022663B2 (en) * 2000-02-18 2006-04-04 Yeda Research And Development Co., Ltd. Oral, nasal and pulmonary dosage formulations of copolymer 1
IL153236A0 (en) * 2000-06-05 2003-07-06 Teva Pharma The use of glatiramer acetate (copolymer 1) in the treatment of central nervous system disorders
US20020077278A1 (en) * 2000-06-05 2002-06-20 Yong V. Wee Use of glatiramer acetate (copolymer 1) in the treatment of central nervous system disorders
CN100438906C (en) * 2000-06-07 2008-12-03 耶达研究及发展有限公司 The use of copolymer 1 and related peptides and polypeptides and T cell treated therewith for neuroprotective therapy
AU6887101A (en) * 2000-06-20 2002-01-02 Caprion Pharmaceuticals, Inc. Copolymers and methods of treating prion-related diseases
WO2002076503A1 (en) 2000-06-20 2002-10-03 Mayo Foundation For Medical Education And Research Treatment of central nervous system diseases by antibodies against glatiramer acetate
IL137460A0 (en) 2000-07-24 2001-07-24 Yeda Res & Dev Identifying antigen clusters for monitoring a global state of an immune system
US20040037828A1 (en) 2002-07-09 2004-02-26 Bar-Ilan University Methods and pharmaceutical compositions for healing wounds
SV2003000753A (en) 2000-12-05 2003-06-16 Brigham & Womens Hospital USE OF ZWITTERIONIC POLYSACARIDS FOR THE SPECIFIC MODULATION OF IMMUNE PROGRESS
GB2369896A (en) 2000-12-06 2002-06-12 Marconi Comm Ltd Tunable optical filter actuator
KR100442122B1 (en) * 2001-07-31 2004-07-30 한국전기연구원 Brushless generator with permanent magnet
DE60237170D1 (en) * 2001-12-04 2010-09-09 Teva Pharma METHOD FOR MEASURING THE ACTIVITY OF GLATIRAMERACETATE
CA2469092C (en) * 2001-12-06 2013-02-19 Yeda Research And Development Co. Ltd Copolymer 1 vaccine and methods for treatment of amyotrophic lateral sclerosis (als)
US20060057107A1 (en) * 2001-12-21 2006-03-16 Shaked Ze Ev Combination treatment for multiple sclerosis
ES2386435T3 (en) 2003-01-07 2012-08-21 Yeda Research And Development Co., Ltd. Vaccine in the form of eye drops containing copolymer 1 for therapeutic immunization
SI1592384T1 (en) * 2003-01-21 2013-03-29 Yeda Research And Development Co., Ltd. The Weizmann Institute Of Science Cop 1 for treatment of inflammatory bowel diseases
WO2004091573A1 (en) * 2003-03-04 2004-10-28 Teva Pharmaceutical Industries, Ltd. Combination therapy with glatiramer acetate and alphacalcidol for the treatment of multiple sclerosis
EP1638581A2 (en) 2003-03-31 2006-03-29 The Brigham And Women's Hospital, Inc. Zwitterionic immunomodulators for the treatment of asthma and allergy
EP1680087A1 (en) * 2003-10-31 2006-07-19 Teva Pharmaceutical Industries Limited Nanoparticles for drug delivery
EP2301569B1 (en) 2003-11-12 2018-05-02 Yeda Research and Development Co. Ltd. Vaccine and method for treatment of neurodegenerative diseases
AU2004297044B2 (en) 2003-12-09 2010-12-09 Yeda Research And Development Co. Ltd. Method and vaccine comprising Copolymer 1 for treatment of psychiatric disorders
AU2005211424A1 (en) * 2004-02-02 2005-08-18 Mixture Sciences, Inc. Peptide mixtures with immunomodulatory activity
KR20060125916A (en) * 2004-03-01 2006-12-06 펩팀문, 인코포레이티드 Methods and compositions for treatment of autoimmune diseases
EP1778286A4 (en) * 2004-03-03 2009-04-08 Teva Pharma Combination therapy with glatiramer acetate and riluzole
US20050260770A1 (en) * 2004-04-01 2005-11-24 Cohen Irun R Antigen array and diagnostic uses thereof
JP2007536278A (en) 2004-05-07 2007-12-13 ペプチミューン，インコーポレイテッド Method of treating disease using random copolymer
US20060194725A1 (en) * 2004-05-07 2006-08-31 James Rasmussen Methods of treating disease with random copolymers
US7655221B2 (en) * 2004-05-07 2010-02-02 Peptimmune, Inc. Methods of treating disease with random copolymers
ES2432369T3 (en) 2004-06-25 2013-12-03 Id Biomedical Corporation Of Quebec Compositions and methods to treat neurological disorders
EP1797109B1 (en) * 2004-09-09 2016-02-24 Yeda Research And Development Co., Ltd. Mixtures of polypeptides, compositions containing and processes for preparing same, and uses thereof
WO2006029393A2 (en) * 2004-09-09 2006-03-16 Teva Pharmaceutical Industries, Ltd. Process for preparation of mixtures of polypeptides using purified hydrobromic acid
EP1807467B1 (en) * 2004-10-29 2009-08-26 Sandoz AG Processes for preparing glatiramer
US8324641B2 (en) * 2007-06-29 2012-12-04 Ledengin, Inc. Matrix material including an embedded dispersion of beads for a light-emitting device
US20090191173A1 (en) * 2004-11-29 2009-07-30 Michal Eisenbach-Schwartz Induction Of Neurogenesis And Stem Cell Therapy In Combination With Copolymer 1
WO2006083608A1 (en) * 2005-02-02 2006-08-10 Teva Pharmaceutical Industries, Ltd. Process for producing polypeptide mixtures using hydrogenolysis
US20100167983A1 (en) * 2007-10-22 2010-07-01 Teva Pharmaceutical Industries, Ltd. Combination therapy with glatiramer acetate and rasagiline for the treatment of multiple sclerosis
WO2006089164A1 (en) * 2005-02-17 2006-08-24 Teva Pharmaceutical Industries, Ltd. Combination therapy with glatiramer acetate and rasagiline for the treatment of multiple sclerosis
EP1891233A4 (en) * 2005-04-25 2010-03-24 Yeda Res & Dev Markers associated with the therapeutic efficacy of glatiramer acetate
WO2007081975A2 (en) * 2006-01-11 2007-07-19 Teva Pharmaceutical Industries, Ltd. Method of treating multiple sclerosis
WO2007092451A2 (en) 2006-02-06 2007-08-16 The Brigham And Women's Hospital, Inc. Zwitterionic polysaccharides for promotion of immune system maturation and health
WO2007120834A2 (en) 2006-04-13 2007-10-25 Peptimmune, Inc. Methods for designing and synthesizing directed sequence polymer compositions via the directed expansion of epitope permeability
JP5374363B2 (en) * 2006-04-28 2013-12-25 モメンタ ファーマシューティカルズ インコーポレイテッド Method for evaluating peptide mixtures
KR100831796B1 (en) * 2006-05-29 2008-05-28 엘지전자 주식회사 An image display device for having time shift function and method for playing of the same
ES2605154T3 (en) 2006-06-28 2017-03-13 Yeda Research And Development Company Limited Copolymer 1 for the treatment of age-related macular degeneration
ATE452140T1 (en) * 2006-07-05 2010-01-15 Momenta Pharmaceuticals Inc IMPROVED PROCESS FOR PRODUCING COPOLYMER-1
EP2381254B2 (en) 2007-06-21 2017-07-19 Momenta Pharmaceuticals, Inc. Copolymer assay
US20090029766A1 (en) * 2007-07-26 2009-01-29 Lutnick Howard W Amusement gaming access and authorization point
EP2173766A1 (en) * 2007-07-31 2010-04-14 Natco Pharma Limited Process for the preparation glatiramer acetate (copolymer-1)
EP2586460A1 (en) 2007-10-16 2013-05-01 Peptimmune, Inc. Method for designing and preparing vaccines comprising directed sequence polymer composition via the directed expansion of epitopes
WO2009062132A2 (en) 2007-11-09 2009-05-14 California Institute Of Technology Immunomodulating compounds and related compositions and methods
CA2702437C (en) * 2007-11-28 2013-06-25 Teva Pharmaceutical Industries Ltd. Method of delaying the onset of clinically definite multiple sclerosis
RU2010146489A (en) 2008-04-16 2012-05-27 Момента Фармасьютикалз, Инк. (Us) ANALYSIS OF THE AMINO ACIDS POLYMER COMPOSITIONS
HUE025042T2 (en) * 2008-08-07 2016-07-28 Sigma Aldrich Co Llc Preparation of low molecular weight polylysine and polyornithine in high yield
US8212002B2 (en) * 2008-08-07 2012-07-03 Scinopharm Taiwan Ltd Synthesis of glatiramer acetate
US9617313B2 (en) 2008-12-24 2017-04-11 Synthon Bv Process for purifying a polymer mixture
EP2414384B2 (en) 2009-04-03 2023-05-03 Momenta Pharmaceuticals, Inc. Control of copolymer compositions
WO2010140157A1 (en) * 2009-06-04 2010-12-09 Council Of Scientific & Industrial Research Aprocess for the preparation of copolymer - 1 (cop-i), composed of l-alanine, l-lysine, l-glutamic acid and l-tyrosine-drug for the treatment of multiple sclerosis
PL2275086T3 (en) 2009-07-15 2012-09-28 Teva Pharma Reduced volume formulation of glatiramer acetate and methods of administration
US8920373B2 (en) 2009-07-15 2014-12-30 Teva Pharmaceutical Industries, Ltd. Reduced volume formulation of glatiramer acetate and methods of administration
US8691790B2 (en) * 2009-07-27 2014-04-08 James Layne Boucher Therapy of neurological inflammatory diseases with (5'-deoxy-5'-adenosyl) cobamamide, recombinant human growth hormone, interleukins IL-1, IL-6, IL-11, epidermal growth factor, and physiotherapy
PT2405749E (en) 2009-08-20 2013-07-22 Yeda Res & Dev Low frequency glatiramer acetate therapy
USRE49251E1 (en) 2010-01-04 2022-10-18 Mapi Pharma Ltd. Depot systems comprising glatiramer or pharmacologically acceptable salt thereof
US8377885B2 (en) 2010-01-04 2013-02-19 Mapi Pharma Ltd. Depot systems comprising glatiramer or pharmacologically acceptable salt thereof
PT3536333T (en) 2010-01-04 2022-11-11 Mapi Pharma Ltd Depot system comprising glatiramer acetate
WO2011086470A1 (en) 2010-01-13 2011-07-21 Ramot At Tel-Aviv University Ltd Treatment of multiple sclerosis
US8759302B2 (en) * 2010-03-16 2014-06-24 Teva Pharmaceutical Industries, Ltd. Methods of treating a subject afflicted with an autoimmune disease using predictive biomarkers of clinical response to glatiramer acetate therapy in multiple sclerosis
ES2694100T3 (en) 2010-04-07 2018-12-18 California Institute Of Technology Vehicle to distribute a compound in a mucous membrane and compositions, procedures and related systems
CA2797227A1 (en) * 2010-04-27 2011-11-10 Dr. Reddy's Laboratories Ltd. Preparation of polypeptides and salts thereof
WO2011146910A1 (en) 2010-05-20 2011-11-24 Round June L Antigen specific tregs and related compositions, methods and systems
WO2012016042A2 (en) * 2010-07-29 2012-02-02 Dr. Reddy's Laboratories Ltd. Glatiramer acetate molecular weight markers
PT2627669T (en) 2010-10-11 2016-11-24 Teva Pharma Cytokine biomarkers as predictive biomarkers of clinical response for glatiramer acetate
EP2675824B1 (en) 2011-02-14 2017-09-27 USV Private Limited Copolymer-1, process for preparation and analytical methods thereof
EP2699317B1 (en) 2011-04-21 2016-08-10 Mapi Pharma Limited Random pentapolymer for treatment of autoimmune diseases
WO2012150495A1 (en) 2011-05-05 2012-11-08 National Institute Of Immunology Synthetic peptides and random copolymers for the treatment of autoimmune disorders
WO2013009864A1 (en) 2011-07-11 2013-01-17 Momenta Pharmaceuticals, Inc. Structure assessment of heterogeneous polypeptide mixtures
WO2013009885A2 (en) 2011-07-11 2013-01-17 Momenta Pharmaceuticals, Inc. Evaluation of copolymer diethylamide
EP2731617A4 (en) 2011-07-12 2015-07-01 Brigham & Womens Hospital Lipid-containing psa compositions, methods of isolation and methods of use thereof
US8575198B1 (en) 2011-09-07 2013-11-05 Momenta Pharmaceuticals, Inc. In-process control for the manufacture of glatiramer acetate
KR20140101730A (en) 2011-10-10 2014-08-20 테바 파마슈티컬 인더스트리즈 리미티드 Single nucleotide polymorphisms useful to predict clinical response for glatiramer acetate
EP2642290A1 (en) 2012-03-19 2013-09-25 Synthon BV Glatiramer acetate human monocytic cell line-based potency assay
WO2013139728A1 (en) 2012-03-19 2013-09-26 Synthon Bv Glatiramer acetate human monocyte cell-based potency assay
US20140045740A1 (en) * 2012-08-13 2014-02-13 Momenta Pharmaceuticals, Inc. Analysis of glatiramer acetate
CA2884267A1 (en) 2012-10-10 2014-04-17 Teva Pharmaceutical Industries Ltd. Biomarkers predictive for clinical response for glatiramer acetate
WO2014060942A2 (en) * 2012-10-20 2014-04-24 Mahesh Kandula Compositions and methods of for the treatment of multiple sclerosis and neurodegenerative diseases
WO2014128079A1 (en) 2013-02-19 2014-08-28 Synthon B.V. Glatiramer acetate multidose formulation
SI2774639T1 (en) 2013-03-08 2015-05-29 Teva Pharmaceutical Industries, Ltd. Re-useable injector device for syringe
EP2774640B1 (en) 2013-03-08 2014-12-31 Teva Pharmaceutical Industries, Ltd. Re-useable injector device for syringe
AU2014244550B2 (en) 2013-03-14 2018-11-01 Mylan Inc. Glatiramer acetate response biomarker mRNA potency assay
WO2014173463A1 (en) 2013-04-26 2014-10-30 Synthon Bv Glatiramer acetate human monocytic cell line-based potency assay
WO2014182966A1 (en) 2013-05-10 2014-11-13 California Institute Of Technology Probiotic prevention and treatment of colon cancer
CN103265624B (en) * 2013-05-27 2015-04-22 成都圣诺生物制药有限公司 Method for preparing copaxone
CN104371012A (en) * 2013-08-12 2015-02-25 深圳翰宇药业股份有限公司 Synthesis method of glatiramer acetate
UY35790A (en) 2013-10-21 2015-05-29 Teva Pharma GENETIC MARKERS THAT PREACH THE RESPONSE TO THE GLATIRAMER ACETATE
CA2928084A1 (en) 2013-10-24 2015-04-30 Mylan Inc. Human t cell line assay for evaluating the immunologic identity of glatiramer acetate preparations
JP2017503169A (en) 2013-12-31 2017-01-26 イエダ・リサーチ・アンド・デベロツプメント・カンパニー・リミテツド Diagnosis of systemic lupus erythematosus using oligonucleotide antigens
RU2690670C2 (en) 2014-03-12 2019-06-05 Ида Рисерч Энд Дивелопмент Ко., Лтд Reduced levels or activity of systemic regulatory t cells for treating disease or cns injury
CN104844697B (en) 2014-09-26 2018-10-23 深圳翰宇药业股份有限公司 The preparation method of acetic acid copaxone
US9155775B1 (en) 2015-01-28 2015-10-13 Teva Pharmaceutical Industries, Ltd. Process for manufacturing glatiramer acetate product
US11047855B2 (en) 2015-03-01 2021-06-29 Immunarray Ltd. Diagnosis of systemic lupus erythematosus using protein, peptide and oligonucleotide antigens
WO2016201342A1 (en) 2015-06-10 2016-12-15 California Institute Of Technology Sepsis treatment and related compositions methods and systems
CN113637040A (en) 2015-08-19 2021-11-12 哈佛学院院长及董事 Lipidated PSA compositions and methods
ES2744179T3 (en) 2015-09-24 2020-02-24 Chemi Spa Analysis of the molecular weight distribution of complex polypeptide mixtures
ES2707500T3 (en) 2015-11-23 2019-04-03 Chemi Spa Analysis by RP-HPLC of mixtures of complex polypeptides
CN107522774B (en) * 2016-06-22 2021-07-02 深圳翰宇药业股份有限公司 Real-time control method for piperidine residual quantity in glatiramer acetate preparation process
WO2018002930A1 (en) 2016-06-30 2018-01-04 Stem Cell Medicine Ltd. Treatment of inflammatory bowel disease with long acting glatiramer and adipose-derived stem cells
CA3030974A1 (en) 2016-07-15 2018-01-18 President And Fellows Of Harvard College Glycolipid compositions and methods of use
BR112019003131A2 (en) 2016-08-28 2019-05-21 Mapi Pharma Ltd. Process for preparing microparticles containing glatiramer acetate
FI3506921T3 (en) 2016-08-31 2023-07-21 Mapi Pharma Ltd Depot systems comprising glatiramer acetate
CN110382052A (en) 2017-03-26 2019-10-25 Mapi医药公司 The copaxone store system of multiple sclerosis for therapeutic advance type form
WO2018211486A1 (en) 2017-05-15 2018-11-22 Stem Cell Medicine Ltd. Treatment of multiple sclerosis with long acting glatiramer and adipose-derived stem cells
CA3062123A1 (en) 2017-05-15 2018-11-22 Stem Cell Medicine Ltd. Treatment of multiple sclerosis with adipose-derived stem cells
WO2019175869A1 (en) 2018-03-12 2019-09-19 Yeda Research And Development Co. Ltd Treatment of a heart disease

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL36670A (en) * 1971-04-21 1974-09-10 Sela M Therapeutic basic copolymers of amino acids
US4444760A (en) 1983-06-17 1984-04-24 Merck & Co., Inc. Purification and characterization of a protein fibroblast growth factor
JPS6053535A (en) 1983-09-02 1985-03-27 Nitto Boseki Co Ltd Production of regular polyaminoacid resin
SU1182051A1 (en) 1984-04-28 1985-09-30 Таджикский государственный университет им.В.И.Ленина Polytripeptides possessing oenantic selectivity in reactions of hydrolysis of carbobenzoxy-d-1 alanine n-nitrophenyl esters
DE3681144D1 (en) 1985-06-18 1991-10-02 Univ Emory USE OF BIOLOGICALLY ACTIVE COPOLYMERS FOR THE PRODUCTION OF A MEDICINAL PRODUCT FOR STIMULATING THE GROWTH OF ANIMALS.
DD257174A3 (en) 1985-12-20 1988-06-08 Ve Forschungszentrum Biotechno PROCESS FOR PREPARING THE PEPTIDES Z ALA ALA LON P NITRANILIDE OR Z ASP ASP PHE OME WITH METALOPROTEASE
SU1469826A1 (en) 1986-05-30 1995-11-20 Институт Высокомолекулярных Соединений Ан Ссср Copolymer of l-lysine and l-glutamic acid containing side groups and showing prolonged hypotensive activity and compensatory effect at hemorrhagic shock, and a method of its preparing
US4828706A (en) 1988-03-07 1989-05-09 Spectrum Medical Industries Process for performing a dialysis operation
US4908404A (en) * 1988-08-22 1990-03-13 Biopolymers, Inc. Synthetic amino acid-and/or peptide-containing graft copolymers
DE8900366U1 (en) * 1989-01-13 1989-08-03 Indag Gesellschaft Fuer Industriebedarf Mbh, 6904 Eppelheim, De
CA2009996A1 (en) * 1989-02-17 1990-08-17 Kathleen S. Cook Process for making genes encoding random polymers of amino acids
SU1690368A1 (en) 1989-07-20 1995-08-20 Институт Высокомолекулярных Соединений Ан Ссср Statistic copolymers as low toxic compounds having prolonged hypotensive action and method for their production
DE3930733A1 (en) 1989-09-14 1991-03-28 Roehm Gmbh METHOD FOR PRODUCING A COMPLEX MEDICINAL PRODUCT
JP2653255B2 (en) * 1990-02-13 1997-09-17 武田薬品工業株式会社 Long-term sustained release microcapsules
EP0613496B1 (en) * 1991-11-12 1999-01-20 E.I. Du Pont De Nemours And Company Collagen-like polypeptides
IL113812A (en) 1994-05-24 2000-06-29 Yeda Res & Dev Copolymer-1 pharmaceutical compositions containing it and its use
US6214791B1 (en) * 1997-01-10 2001-04-10 Yeda Research And Development Co. Ltd. Treatment of multiple sclerosis through ingestion or inhalation of copolymer-1
AU7368798A (en) 1997-05-06 1998-11-27 Quanta Vision Tissue analysis apparatus
JP4328050B2 (en) * 2000-01-20 2009-09-09 イエダ リサーチ アンド デベロップメント カンパニー リミテッド Use of Copolymer 1, related peptides and polypeptides and T cells treated with them for neuroprotective therapy
US6936539B2 (en) * 2003-09-24 2005-08-30 Micron Technology, Inc. Antireflective coating for use during the manufacture of a semiconductor device

Also Published As

Publication number Publication date
CN1152874A (en) 1997-06-25
CN1310673C (en) 2007-04-18
US6362161B1 (en) 2002-03-26
CZ341096A3 (en) 1997-06-11
EP0762888B1 (en) 2002-02-06
NO964976L (en) 1997-01-23
US5800808A (en) 1998-09-01
MD1443G2 (en) 2000-11-30
PL317331A1 (en) 1997-04-01
JP3715600B2 (en) 2005-11-09
SK283699B6 (en) 2003-12-02
JP2003105000A (en) 2003-04-09
NO324528B1 (en) 2007-11-12
MD1443F1 (en) 2000-04-30
ATE212857T1 (en) 2002-02-15
DE10299030I1 (en) 2003-01-23
US7625861B2 (en) 2009-12-01
PT762888E (en) 2002-07-31
DE69525340T2 (en) 2002-09-19
BR9507758A (en) 1997-09-23
US6939539B2 (en) 2005-09-06
CA2191088C (en) 2004-09-28
US7199098B2 (en) 2007-04-03
US6342476B1 (en) 2002-01-29
US6054430A (en) 2000-04-25
ES2172586T3 (en) 2002-10-01
NL300096I1 (en) 2002-10-01
US6048898A (en) 2000-04-11
US5981589A (en) 1999-11-09
GEP20002205B (en) 2000-08-25
NL300096I2 (en) 2003-02-03
US20030064914A1 (en) 2003-04-03
EP0762888A4 (en) 1997-04-16
US20070117757A1 (en) 2007-05-24
BRPI9507758B1 (en) 2021-03-16
HU223473B1 (en) 2004-07-28
US6620847B2 (en) 2003-09-16
SI0762888T1 (en) 2002-08-31
CZ292247B6 (en) 2003-08-13
DE69525340D1 (en) 2002-03-21
CN1174753C (en) 2004-11-10
TJ392B (en) 2004-10-13
PL181026B1 (en) 2001-05-31
CN1626238A (en) 2005-06-15
IL113812A0 (en) 1995-08-31
KR100403750B1 (en) 2006-02-13
WO1995031990A1 (en) 1995-11-30
KR970703154A (en) 1997-07-03
DK0762888T3 (en) 2002-05-27
FI964600A (en) 1996-12-05
IL133890A0 (en) 2001-04-30
EP0762888A1 (en) 1997-03-19
JPH10500955A (en) 1998-01-27
LU90987I2 (en) 2003-02-25
HUT75672A (en) 1997-05-28
SK149396A3 (en) 1997-08-06
NZ287335A (en) 1999-02-25
IL113812A (en) 2000-06-29
AU2602195A (en) 1995-12-18
EE03423B1 (en) 2001-06-15
NO964976D0 (en) 1996-11-22
UA62908C2 (en) 2004-01-15
US20040106554A1 (en) 2004-06-03
EE9600170A (en) 1997-06-16
US8367605B2 (en) 2013-02-05
FI120236B (en) 2009-08-14
HU9603243D0 (en) 1997-01-28
US20050171286A1 (en) 2005-08-04
US20120077754A1 (en) 2012-03-29
HK1008657A1 (en) 1999-05-14
FI964600A0 (en) 1996-11-15

Similar Documents

Publication Publication Date Title
CA2191088A1 (en) Copolymer-1 improvements in compositions of copolymers
CA2099377A1 (en) Superior stain resistant compositions
NZ333993A (en) Compositions of EPO having a single covalently bound N-terminal water-soluble polymer
EP1056469A4 (en) Novel peptide copolymer compositions
EP1262527A3 (en) Antistatic polymer compositions
CA2184551A1 (en) Iron dextran formulations
WO1999017711A3 (en) Autophobic hairspray compositions
SG38904A1 (en) High performance polymer compositions
AU2981299A (en) Nylon 6 or 66 based compositions and films formed therefrom
AU5117790A (en) Improved clear organosiloxane compositions
CA2211568A1 (en) Organosilicon compounds containing amino groups, their preparation and their use
AU3743797A (en) Polysulfone copolymer compositions
IL95773A0 (en) Polymer compositions comprising graft copolymer impact modifier
ZA954220B (en) Copolymer-1: compositions of copolymers
FR2656321B1 (en) COMPOSITIONS COMPRISING ETHYLENE COPOLYMERS.
CA2104079A1 (en) Hydrolyzed Zein as Hair Fixative in Hair Compositions
EP0647703A3 (en) Polymer compositions of improved compatibility in oil.
AU586551B2 (en) High impact nylon block copolymer compositions
CA2347809A1 (en) Fabric care compositions having reduced fabric abrasion
CA2305666A1 (en) Resin composition of improved elongation
AU4608289A (en) Toughened polyamide compositions having improved properties

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry

Effective date: 20150525